Holen Sie sich die Stockscreener-App
59.43
0.35%
0.21
Handel nachbörslich:
59.43
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Nisa Investment Advisors LLC Sells 64,955 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Nisa Investment Advisors LLC - Defense World
Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet - Yahoo Finance
How To Trade (RYTM) - Stock Traders Daily
Soligenix (NASDAQ:SNGX) & Rhythm Pharmaceuticals (NASDAQ:RYTM) Head to Head Contrast - Defense World
Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? - MSN
Earnings call transcript: Rhythm Pharmaceuticals Q3 2024 sees growth - MSN
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Exploring High Growth Tech Stocks in January 2025 - Simply Wall St
Earnings call transcript: Rhythm Pharmaceuticals Q3 2024 sees growth By Investing.com - Investing.com Canada
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price - Simply Wall St
JPMorgan Chase & Co. Sells 58,554 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Long Term Trading Analysis for (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $68.09 Average Target Price from Analysts - Defense World
Head to Head Review: ABVC BioPharma (NASDAQ:ABVC) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm gets FDA approval for Imcivree for toddlers - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Harbor Capital Advisors Inc. Sells 11,116 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ: RYTM) Reports Strong Growth in Revenue and Clinical Development Initiatives - Defense World
Rhythm Pharmaceuticals price target raised to $60 from $58 at BofA - MSN
Rhythm Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
Rhythm Pharmaceuticals Reports Growth and Expands Pipeline - TipRanks
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones - The Manila Times
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product - The Bakersfield Californian
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter - GlobeNewswire
Rhythm Pharmaceuticals Delivers Record $130M Revenue in 2024, Q4 Sales Surge 26% - StockTitan
Principal Financial Group Inc. Has $1.71 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Principal Financial Group Inc. Buys 23,054 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Jefferies Financial Group - Defense World
Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential - Yahoo Finance
Jefferies Financial Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Where are the Opportunities in (RYTM) - Stock Traders Daily
Stifel Financial Corp Has $1.04 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Market Outperform Rating from JMP Securities - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Buy Rating from HC Wainwright - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given "Market Outperform" Rating at JMP Securities - MarketBeat
Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years - Yahoo Finance
Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
FDA nod for Rhythm Pharma’s Imcivree - The Pharma Letter
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Price Target at $64.67 - Defense World
Franklin Resources Inc. Purchases 26,739 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Barclays PLC Buys 47,166 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharma Modifies Trials of Genetic Obesity Medicine; Shares Drop - Marketscreener.com
Oppenheimer Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation - MSN
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children - MarketWatch
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential - Benzinga
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® - GlobeNewswire
Rhythm Pharma's IMCIVREE Wins FDA Approval for Rare Obesity Treatment in Young Children - StockTitan
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Oppenheimer - MarketBeat
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals - Benzinga
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):